STERIS (STE) Stock Forecast & Price Target

Steris is well positioned to sustain a mid-single-digit to high-single-digit organic growth profile, with FQ1-27 revenue of $1,493M up 6.2% organically and FY27 guidance maintained at 6-7% revenue growth and $11.10-$11.30 in adjusted EPS. Its outlook is supported by Healthcare Services strength, including 10% service growth, 9% consumables growth, 14 consecutive quarters of double-digit demand, and Healthcare equipment orders up 8% with backlog at a 3-year high, which should improve visibility into future revenue. Margins and capital allocation also reinforce the bullish case, as gross margin reached 46.0%, operating margin was 23.8%, gross leverage was about 1.2x, and the company has a new $1B buyback program alongside bolt-on acquisitions and a $600M North Carolina investment aimed at long-term capacity and returns.

Steris is vulnerable to a weaker operating backdrop because its results depend heavily on procedure volumes, while capital equipment demand can be lumpy, making revenue and earnings less predictable. The company also faces margin pressure from supply chain disruptions and inflationary costs, which can erode profitability even if end-market demand remains stable. On top of that, potential declines in global healthcare spending, unfavorable tariff policy changes, and new FDA regulatory actions could further weigh on growth and investor confidence.